Cellular Logistics
Pre-clinicalCFX™ is the first of its kind therapeutic biomaterial manufactured using induced pluripotent stem cell technology. Local administration of CFX™ can prevent the pathological changes that lead to heart failure following an acute injury such as myocardial infarction. Additionally, CFX™, in combination with therapeutic stem cells, can remuscularize scarred myocardium to restore heart function in chronic heart failure.
About
CFX™ is the first of its kind therapeutic biomaterial manufactured using induced pluripotent stem cell technology. Local administration of CFX™ can prevent the pathological changes that lead to heart failure following an acute injury such as myocardial infarction. Additionally, CFX™, in combination with therapeutic stem cells, can remuscularize scarred myocardium to restore heart function in chronic heart failure.
Funding History
2Total raised: $5M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile